Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Goodwill (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Goodwill for 16 consecutive years, with $9.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Goodwill fell 83.42% to $9.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.5 million, a 83.42% decrease, with the full-year FY2024 number at $56.3 million, down 1.3% from a year prior.
  • Goodwill was $9.5 million for Q3 2025 at Harvard Bioscience, down from $10.2 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $58.4 million in Q2 2021 to a low of $9.0 million in Q1 2025.
  • A 5-year average of $49.4 million and a median of $56.6 million in 2024 define the central range for Goodwill.
  • Peak YoY movement for Goodwill: grew 2.57% in 2021, then tumbled 84.2% in 2025.
  • Harvard Bioscience's Goodwill stood at $57.7 million in 2021, then fell by 2.48% to $56.3 million in 2022, then increased by 1.43% to $57.1 million in 2023, then fell by 1.3% to $56.3 million in 2024, then plummeted by 83.09% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Goodwill are $9.5 million (Q3 2025), $10.2 million (Q2 2025), and $9.0 million (Q1 2025).